Schulungsreihe pDL Inhalativa: Ellipta

This video explains the correct handling of the Ellipta dry powder inhaler and its special features for healthcare professionals. It demonstrates, in particular, how to instruct patients. To raise awareness of potential and especially relevant sources of error when using this device, these are presented within the context of patient training. A simplified procedure for administering the service is shown. For the recommended procedure, please refer to the information on the pDL Campus website under pDL Inhalativa. The video was produced with the utmost care to ensure that the handling is demonstrated correctly. Adapt the instructions to the individual knowledge and needs of your patients. . ... 0:00 Intro 0:47 Introduction 1:17 Demonstration of the correct inhalation technique 2:35 Practicing inhalation with typical user errors 4:15 Key points of the consultation 4:52 Additional consultation notes 07:13 Outro Device type: Blister-based dry powder inhaler Mechanism: • Drug doses are individually packaged for each actuation and are prepared by opening the protective flap • Aerosol generation through a combination of device resistance and the shear forces of forced inspiration Inhalation technique: • Smooth, forceful inhalation • The device's resistance necessitates a moderate breath strength Key messages of the consultation: • The core of the breathing maneuver is smooth, forceful inhalation followed by a 5-10 second pause • Sensitize patients who regularly use a dry powder inhaler and a DPI to the different inhalation maneuver • Maintain an upright posture during Dosage • Avoid covering the air vents during inhalation Available preparations: The Ellipta is available with different active ingredients on the German market: • Anoro® - Umeclidinium + Vilanterol (anticholinergic + long-acting beta-sympathomimetic) • Elebrato® - Fluticasone furoate + Umeclidinium + Vilanterol (glucocorticoid + anticholinergic + long-acting beta-sympathomimetic) • Incruse® - Umeclidinium (anticholinergic) • Laventair® - Umeclidinium + Vilanterol (anticholinergic + long-acting beta-sympathomimetic) • Relvar® - Fluticasone furoate + Vilanterol (glucocorticoid + long-acting beta-sympathomimetic) • Revinty® - Fluticasone furoate + Vilanterol (Glucocorticoid + long-acting beta-sympathomimetic) • Rolufta® - Umeclidinium (anticholinergic) • Trelegy® - Fluticasone furoate + Umeclidinium + Vilanterol (glucocorticoid + anticholinergic + long-acting beta-sympathomimetic) The active ingredients in Ellipta inhalers are for long-term therapy and not suitable for the acute treatment of an attack of shortness of breath. Further links: Materials and information on the administration of pDL inhalers: https://www.abda.de/pharmazeutische-d... pDL Campus live! continuing education series: https://www.pdlcampus-live.de/pdl/liv... Sources: GSK - GalaxoSmithKline (as of 07/2023): Patient Information Leaflet: Information for patients; Relvar Ellipta 92 micrograms/22 micrograms single-dose inhalation powder, Relvar Ellipta 184 micrograms/22 micrograms single-dose inhalation powder, last accessed on November 13, 2025 at: https://www.gsk-kompendium.at/pil-rel... German Respiratory Society: Inhalation with Ellipta; last accessed on November 13, 2025 at: https://www.atemwegsliga.de/ellipta.html Yellow List (05/2024): Relvar Ellipta 184 micrograms/22 micrograms Fd Pharma single-dose inhalation powder; Last accessed on November 13, 2025, at: https://www.gelbe-liste.de/produkte/R... Jeaschke, Robert/Spindler, Thomas: Inhalativa. Stuttgart: Deutscher Apotheker Verlag 2023. p. 60 Kircher W. Arzneiformen richtig Anwendungsanwendung: Sachgerechte Gebrauch und Lagerung der Arzneimittel. 4th, completely revised edition. Stuttgart: Deutscher Apotheker Verlag 2016. © BAK – Bundesapothekerkammer Status: December 2025